ESSA Pharma Inc. (EPIX) News
Filter EPIX News Items
EPIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EPIX News Highlights
- EPIX's 30 day story count now stands at 5.
- Over the past 26 days, the trend for EPIX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about EPIX are ESSA, AR and MS.
Latest EPIX News From Around the Web
Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.
ESSA Pharma Appoints Lauren Merendino to its Board of DirectorsESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. |
ESSA Pharma to Present at 2023 Jefferies Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York. |
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide…By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen receptor (AR). The AR is the main signaling |
ESSA Pharma to Present at JMP Securities Life Sciences ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York. |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2023. All references to "$" in this release refer to United States dollars, unless otherwise indicated. |
ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 2:00 p.m. Eastern Time. |
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate CancerESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen") to enable evaluation of ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI |
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time. |
ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measuresKey Insights Institutions' substantial holdings in ESSA Pharma implies that they have significant influence over the... |